Hyundai Pharm to launch its 20 mg Alzheimer’s drug - KBR

1 year ago 64

본문영역

현재위치

Hyundai Pharm to motorboat its 20 mg Alzheimer’s drug

기자명 Marianne Chang
Published 2023.01.02 11:12

Hyundai Pharmaceutical said connected Monday that it will motorboat a 20mg dose of Dimantine (ingredient: memantine hydrochloride), an Alzheimer's illness attraction that improved patient convenience, successful the home market.

memantine hydrochloride), an Alzheimer's illness attraction that improves the convenience of taking medicine successful Korea.

Dimantine is simply a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor-based cause licensed to treat moderate to terrible Alzheimer's disease. It blocks NMDA receptors abnormally activated by synaptic elevated glutamates to support learning and memory-related physiological activity, thereby preventing oregon slowing the disease, said a Hyundai Pharmaceutical official.

Previously, Hyundai Pharm sold the cause successful 5mg and 10mg formulations but the caller 20mg formulation was lone approved for merchantability by the Ministry of Food and Drug Safety (MFDS) connected Oct. 28.

Accordingly, the 20mg oral medication formulation tin present beryllium administered erstwhile a day, to amended medicine compliance for patients and guardians compared to the existing 10mg formulation which needs to beryllium administered doubly a day.

According to the company, pharmacokinetic tests and comparative objective trials showed that the effectiveness and information of Dimantine’s 20 mg and 10mg formulations were similar.

In addition, the minimum requirements for Alzheimer’s patients to suffice for security sum is little than 20 for Mini-mental State Examination (MMSE) and a Clinical Dementia Rating (CDR) of 2-3 oregon Global Dementia Scale (GDS) of 4-7.

"It is important to guarantee that Alzheimer’s patients tin instrumentality medicine continuously without forgetting the clip and frequence to instrumentality the medicine," An authoritative from Hyundai Pharmaceutical said, "We expect this to assistance trim the anticipation of inaccurate doses by utilizing a azygous regular dose to supply caller attraction options for patients."

As of 10:05 a.m. connected Monday, Hyundai Pharmaceutical’s shares stood astatine 4,870 won ($3.84), up by 1.67 percent from the erstwhile trading day.